stonks4u
Log inSign up free
OSTX logo

OSTX OS Therapies Incorporated

New York Stock Exchange Arca · Biotechnology · Healthcare

$1.46
-0.17 (-10.19%)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide link…

Market Cap: $66.26Mostherapies.com

Price

No data yet.

Signal Score (90d)

75
75
Aug 17Aug 17

Quote

Day Range
$1.44 – $1.59
52-Week Range
$1.15 – $2.57
Volume
$428.9K
Market Cap
$66.26M
50-Day Avg
$1.67
200-Day Avg
$1.60
Prev Close
$1.62
Open
$1.59

Valuation & Ratios

P/E Ratio
-1.43
EPS
$-0.98
P/B Ratio
-6.72
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
0.03
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
+471.7%
Return on Assets
-420.4%
FCF Yield
-34767.1%
EV/EBITDA
-1.43

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-28.75M$-0.98
2024$0.00$-8.88M$-0.52
2023$0.00$-7.79M$-0.39
2022$0.00$-6.25M$-0.28
2021$0.00$-7.42M$-0.33

Social Signal Score

25
5d
26
1 mentions
—
30d
25
1 mentions
—
60d
25
1 mentions
—
90d
25
1 mentions
—
news: 1

Earnings

Fri, Nov 13(in 3 months)

Consensus estimate $-0.17 per share

0of 7 quarters beat consensus

Typical surprise -58.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-0.20 vs $-0.18miss
  • Mon, May 18$-0.27 vs $-0.17miss
  • Tue, Mar 31$-0.35 vs $-0.14miss
  • Fri, Nov 14$-0.21 vs $-0.16miss
  • Tue, Aug 19$-0.19 vs $-0.15miss
  • Thu, May 15$-0.18 vs $-0.11miss

Estimates and results for OSTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by OSTX officers and directors.

Bought
—

0 trades

Sold
$642k

5 trades

  • Auerbach Shalomsold
    10 percent owner·82,000 @ $2.00·$164k·May 7, 2025·filing
  • Auerbach Shalomsold
    10 percent owner·10,000 @ $1.39·$14k·Apr 10, 2025·filing
  • Auerbach Shalomsold
    10 percent owner·50,012 @ $1.35·$68k·Apr 9, 2025·filing
  • Auerbach Shalomsold
    10 percent owner·100,000 @ $2.84·$284k·Feb 14, 2025·filing
  • Auerbach Shalomsold
    10 percent owner·16,720 @ $6.74·$113k·Jan 15, 2025·filing

83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

OSTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsnewsfilecorp.com·6h ago·Negative

    … U.K. waives Pediatric Investigation Plan (PIP) requirement New York and Rockville, Maryland--(Newsfile Corp. - August 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today reported financial results for the second fiscal quarter ended June 30, 2026, and provided business and regulatory updates. The Company is seeking to obtain a Biologics License Application (BLA) under the Accelerate…

    View source ↗